Table 3.

Multivariate Cox model for study cohorts undergoing HCT for MPN-BP vs de novo AML

nHR (95% CI)P
aGVHD II-IV    
 De novo AML 4693 1.00 (Reference) .32 
 MPN-BP 176 1.12 (0.90-1.40)  
aGVHD III-IV    
 De novo AML 4677 1.00 (Reference) .44 
 MPN-BP 174 1.14 (0.81-1.60)  
cGVHD    
 De novo AML 4693 1.00 (Reference) .47 
 MPN-BP 176 1.05 (0.93-1.18)  
OS    
 In remission*    
  De novo AML 3511 1.00 (Reference) .003 
  MPN-BP 101 1.40 (1.12 - 1.76)  
 Active leukemia†    
  De novo AML 1238 1.00 (Reference) .59 
  MPN-BP 76 0.93 (0.72 - 1.20)  
Relapse    
 In remission*    
  De novo AML 3461 1.00 (Reference) <.0001 
  MPN-BP 101 2.18 (1.69-2.80)  
 Active leukemia†    
  De novo AML 1208 1.00 (Reference) .30 
  MPN-BP 76 1.16 (0.88 - 1.54)  
NRM    
 De novo AML 4669 1.00 (Reference) .92 
 MPN-BP 177 1.02 (0.74-1.41)  
PFS    
 De novo AML 4669 1.00 (Reference) .0003 
 MPN-BP 177 1.35 (1.15-1.59)  
nHR (95% CI)P
aGVHD II-IV    
 De novo AML 4693 1.00 (Reference) .32 
 MPN-BP 176 1.12 (0.90-1.40)  
aGVHD III-IV    
 De novo AML 4677 1.00 (Reference) .44 
 MPN-BP 174 1.14 (0.81-1.60)  
cGVHD    
 De novo AML 4693 1.00 (Reference) .47 
 MPN-BP 176 1.05 (0.93-1.18)  
OS    
 In remission*    
  De novo AML 3511 1.00 (Reference) .003 
  MPN-BP 101 1.40 (1.12 - 1.76)  
 Active leukemia†    
  De novo AML 1238 1.00 (Reference) .59 
  MPN-BP 76 0.93 (0.72 - 1.20)  
Relapse    
 In remission*    
  De novo AML 3461 1.00 (Reference) <.0001 
  MPN-BP 101 2.18 (1.69-2.80)  
 Active leukemia†    
  De novo AML 1208 1.00 (Reference) .30 
  MPN-BP 76 1.16 (0.88 - 1.54)  
NRM    
 De novo AML 4669 1.00 (Reference) .92 
 MPN-BP 177 1.02 (0.74-1.41)  
PFS    
 De novo AML 4669 1.00 (Reference) .0003 
 MPN-BP 177 1.35 (1.15-1.59)  

CI, confidence interval; HR, hazard ratio.

*

In remission: CR1/CR2 for de novo AML and blasts <5% in peripheral blood and bone marrow for MPN-BP and post-MDS AML.

†

Active leukemia: blasts in peripheral blood or bone marrow <5%.

View Large